BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Market News

Lowe’s cuts full-year profit guidance as DIY weakness persists despite Pro strength

Moe Alsumidaie by Moe Alsumidaie
August 20, 2026
in Market News
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Lowe’s Companies narrowed its fiscal 2026 earnings outlook on Wednesday, reducing adjusted diluted EPS guidance to approximately $12.25 from a prior range of $12.25 to $12.75, and tightening comparable sales to flat from a prior flat-to-up-2% range. The cuts reflect first-half operational results and what the company describes as “current demand trends”, a euphemism for sustained weakness in discretionary do-it-yourself spending that is offsetting gains in its professional and online channels. The company’s second quarter showed the tension: comparable sales rose just 0.2%, held up entirely by Pro and home services strength plus a 15.7% increase in online sales, while the DIY customer retreated.

In the quarter ended July 31, 2026, Lowe’s reported net sales of $25,956 million, up 8.3% from $23,959 million in the prior-year quarter. Diluted EPS held flat at $4.27 versus the year-ago quarter, but adjusted diluted EPS rose 1.6% to $4.40 from the prior-year adjusted figure, after excluding $96 million in pre-tax acquisition expenses for Foundation Building Materials and Artisan Design Group. The adjusted EPS figure includes an $0.11 benefit from IEEPA tariff refunds. For the first half of 2026, net sales reached $49,034 million versus $44,888 million in the prior-year six months. The company affirmed its full-year operating margin guidance at 11.2% and adjusted operating margin at 11.6%, both at the low end of prior ranges.

What it means

The headline delta is the downward revision to the earnings ceiling. Lowe’s had guided to adjusted diluted EPS of $12.25 to $12.75; it now guides to approximately $12.25, eliminating the upside. Comparable sales guidance moved from flat-to-up-2% to flat, a meaningful narrowing that signals the company does not expect a DIY recovery in the second half. The culprit is structural, not cyclical: the company explicitly names “persistent DIY macro pressures” as the offset to Pro gains. This is not a one-quarter phenomenon but a sustained trend the company has now internalized into its full-year view.

The operational picture is bifurcated. Pro and online are performing, the quarter’s 0.2% comp sales growth came entirely from these segments and home services, meaning the DIY business declined in absolute terms. The company’s gross margin compressed 77 basis points to 33.04% from 33.81% in the prior-year quarter, a signal that mix (more Pro, less discretionary DIY) and pricing dynamics are working against profitability even as sales grow. Operating income as a percentage of sales fell to 13.67% from 14.48% in the prior quarter, though the six-month operating margin of 12.45% remains above the full-year guidance of 11.2%, suggesting the second half will be materially weaker.

BullScope TerminalLOWES COMPANIES INC was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

The open question is whether the Pro and online momentum can sustain if DIY weakness deepens. The company’s guidance assumes flat comps for the full year, implying the second half will be weaker than the first half’s implied performance. The tariff refund benefit of $0.11 per share in Q2 is explicitly excluded from the second-half outlook, removing a tailwind. The company does not quantify how much of the Q2 comp sales growth came from Pro versus online, leaving unclear which channel is the true driver and which is more durable.

Source: the company’s 8-K filed 2026-08-19 with the SEC.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read LOWES COMPANIES INC’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Procter & Gamble accelerates organic sales growth to 4% as pricing and volume both contribute

by Moe Alsumidaie
October 23, 2026
0

Procter & Gamble's first quarter of fiscal 2027 delivered organic sales growth of 4 percent, up from the prior year's 3.3 percent, driven b

Read moreDetails

Abbott to split Nutrition into independent company with $8.5 billion in sales by end of 2027

by Moe Alsumidaie
October 22, 2026
0

Abbott announced plans to separate its Nutrition business into a standalone publicly traded company by the end of 2027, creating a $8.5 bil

Read moreDetails

GE Aerospace raises 2026 guidance as commercial services orders surge 58 percent

by Moe Alsumidaie
October 21, 2026
0

GE Aerospace lifted full-year profit and cash flow targets after third-quarter orders jumped 58 percent, driven by a backlog of over $170 b

Read moreDetails

Biohaven licenses Japan and Asia rights to Graves’ disease candidate for $80 million upfront and 20% royalties

by Moe Alsumidaie
October 19, 2026
0

Biohaven has licensed its lead extracellular IgG degrader, BHV-1300, to Ono Pharmaceutical for exclusive development and commercialization

Read moreDetails

UnitedHealth’s operating margin surges as medical cost discipline offsets revenue decline

by Moe Alsumidaie
October 15, 2026
0

UnitedHealth Group raised full-year earnings guidance to at least $20.50 per share after third-quarter operating earnings jumped 53 percent

Read moreDetails
Next Post

Honeywell elevates Building Automation chief to lead Process Technology as Ken West departs

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

ExxonMobil: A Machine That Prints Cash While the Market Argues About the Price Tag

August 28, 2026

Caterpillar renews three-year credit facility with unchanged $4 billion commitment as borrowing costs shift to SOFR

September 24, 2026

Evidence Sheet: Costco Wholesale (COST)

October 8, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.